Bleximenib

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameBleximenib
Drug Alias NameJNJ-75276617JNJ75276617JNJ-6617
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMenin/Histone-lysine N-methyltransferase 2A MLL inhibitors
TargetsHistone-lysine N-methyltransferase 2AMenin
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Pharmaceutica NV Division Janssen Research and DevelopmentJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A